Based on the key indicators related to Vera Therapeutics' liquidity, profitability, solvency, and operating efficiency, Vera Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March. At present, Vera Therapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Short and Long Term Debt Total is expected to grow to about 64.9 M, whereas Other Current Liabilities is forecasted to decline to about 5.5 M. Key indicators impacting Vera Therapeutics' financial strength include:
The essential information of the day-to-day investment outlook for Vera Therapeutics includes many different criteria found on its balance sheet. An individual investor should monitor Vera Therapeutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Vera Therapeutics.
Please note, the presentation of Vera Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Vera Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Vera Therapeutics' management manipulating its earnings.
Vera Therapeutics Stock Summary
Vera Therapeutics competes with Third Harmonic, Cullinan Oncology, Edgewise Therapeutics, Rallybio Corp, and Monte Rosa. Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. Vera Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 29 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Vera Therapeutics's current stock value. Our valuation model uses many indicators to compare Vera Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Vera Therapeutics competition to find correlations between indicators driving Vera Therapeutics's intrinsic value. More Info.
Vera Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Vera Therapeutics' Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Vera Therapeutics' earnings, one of the primary drivers of an investment's value.
Vera Therapeutics Systematic Risk
Vera Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Vera Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Vera Therapeutics correlated with the market. If Beta is less than 0 Vera Therapeutics generally moves in the opposite direction as compared to the market. If Vera Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Vera Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Vera Therapeutics is generally in the same direction as the market. If Beta > 1 Vera Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Vera Therapeutics Thematic Clasifications
Vera Therapeutics is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in Vera Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Vera Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Vera Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio
0.19
At present, Vera Therapeutics' Price Earnings To Growth Ratio is projected to increase slightly based on the last few years of reporting.
Vera Therapeutics February 25, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Vera Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Vera Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Vera Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Vera Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Vera Therapeutics's daily price indicators and compare them against related drivers.
When running Vera Therapeutics' price analysis, check to measure Vera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vera Therapeutics is operating at the current time. Most of Vera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vera Therapeutics' price. Additionally, you may evaluate how the addition of Vera Therapeutics to your portfolios can decrease your overall portfolio volatility.